UCB SA (OTCMKTS:UCBJY) Sees Significant Drop in Short Interest

UCB SA (OTCMKTS:UCBJY) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totaling 11,143 shares, a drop of 73.7% from the September 15th total of 42,361 shares. Based on an average trading volume of 83,317 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on UCBJY shares. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Zacks Research cut shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 16th. Finally, Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

UCB Price Performance

OTCMKTS UCBJY opened at $114.18 on Monday. UCB has a fifty-two week low of $112.15 and a fifty-two week high of $168.76. The business has a fifty day moving average of $122.91 and a 200-day moving average of $136.75.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.

UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes.